Thyronamines are naturally occurring, chemical relatives of thyroid hormone. Systemic administration of synthetic 3-iodothyronamine (T 1 AM) and -to a lesser extentthyronamine (T 0 AM), leads to acute bradycardia, hypothermia, decreased metabolic rate, and hyperglycemia. This profile led us to hypothesize that the central nervous system is among the principal targets of thyronamines. We investigated whether a low dose i.c.v. infusion of synthetic thyronamines recapitulates the changes in glucose metabolism that occur following i.p. thyronamine administration. Plasma glucose, glucoregulatory hormones, and endogenous glucose production (EGP) using stable isotope dilution were monitored in rats before and 120 min after an i.p. (50 mg/kg) or i.c.v. (0 . 5 mg/kg) bolus infusion of T 1 AM, T 0 AM, or vehicle. To identify the peripheral effects of centrally administered thyronamines, drug-naive rats were also infused intravenously with low dose (0 . 5 mg/kg) thyronamines. Systemic T 1 AM rapidly increased EGP and plasma glucose, increased plasma glucagon, and corticosterone, but failed to change plasma insulin. Compared with i.p.-administered T 1 AM, a 100-fold lower dose administered centrally induced a more pronounced acute EGP increase and hyperglucagonemia while plasma insulin tended to decrease. Both systemic and central infusions of T 0 AM caused smaller increases in EGP, plasma glucose, and glucagon compared with T 1 AM. Neither T 1 AM nor T 0 AM influenced any of these parameters upon low dose i.v. administration. We conclude that central administration of low-dose thyronamines suffices to induce the acute alterations in glucoregulatory hormones and glucose metabolism following systemic thyronamine infusion. Our data indicate that thyronamines can act centrally to modulate glucose metabolism.
Introduction
Thyronamines are a group of naturally occurring, chemical relatives of thyroid hormone (TH) with pronounced and rapid physiologic effects (Scanlan et al. 2004) . Two representatives of the thyronamines, 3-iodothyronamine (T 1 AM) and thyronamine (T 0 AM), have been extracted from rat and mouse brain, heart, liver, and blood. T 1 AM and T 0 AM can theoretically be derived from iodothyronines thyroxine (T 4 ), 3,3 0 ,5-triiodothyronine (T 3 ), and/or 3,3 0 , 5 0 -triiodothyronine (reverse T 3 ) by removal of the carboxylate group on the b-alanine side chain in addition to deiodination. Indeed, thyronamines have recently been identified as isoenzyme-specific substrates of the iodothyronine deiodinases type 1, 2, and 3 (Piehl et al. 2008) . T 1 AM and, to a lesser extent, T 0 AM are potent in vitro agonists of the trace amineassociated receptor type 1 (TAAR1; Scanlan et al. 2004 , Hart et al. 2006 ), a Gs protein-coupled membrane receptor with a broad expression profile (Grandy 2007) . In rodents and humans, high levels of TAAR1 expression are found in liver, kidney, gastrointestinal tract, pancreas, heart, and many areas of the brain (Borowsky et al. 2001 , Bunzow et al. 2001 . Moreover, T 1 AM has the potential to act as an adrenergic receptor a2 (ARa2) agonist in the mouse, explaining in part the decrease in insulin secretion by pancreatic b-cells exposed to thyronamines (Regard et al. 2007) .
When administered to rodents, T 1 AM and T 0 AM have striking effects on physiology. Within minutes after systemic administration, profound hypothermia, bradycardia, and decreased cardiac output occur. In addition, thyronamines rapidly induce metabolic alterations such as decreased metabolic rate and a dramatic shift to preferential lipid fuelling at the cost of carbohydrate oxidation (Scanlan et al. 2004 , Braulke et al. 2007 ). These apparently non-genomic effects are thought to occur via binding to and activating membrane-bound G protein-coupled receptors (GPCRs) such as TAAR1 and ARa2 (Liggett 2004 , Scanlan et al. 2004 . Furthermore, it has been proposed but not yet demonstrated that THs can be converted to thyronamines by enzymatic deiodination and decarboxylation. Since most actions of T 1 AM and T 0 AM are opposite in direction to the bioactive TH T 3 , thyronamines have been hypothesized to play a role in fine-tuning and/or antagonizing T 3 actions on a moment-to-moment timescale (Liggett 2004 , Weatherman 2007 . The brain, in particular the hypothalamus, regulates most of the processes affected by thyronamines (body temperature, cardiac function, and energy metabolism). Moreover, a principal role in regulating hepatic glucose metabolism has recently emerged for the hypothalamus (Obici et al. 2002 , Kalsbeek et al. 2004 , Pocai et al. 2005 . As T 1 AM and T 0 AM are present in rat brain, we hypothesized that these novel compounds could affect glucose metabolism via actions in the central nervous system (CNS).
In the present study, we tested the hypothesis that thyronamines act centrally to induce changes in glucose metabolism using stable isotope dilution and three different routes of administration: systemic (i.p.), central (i.c.v.) , and i.v. in rats. Our results are consistent with the interpretation that T 1 AM and T 0 AM can act centrally to recapitulate the changes in glucose metabolism that occur following systemic thyronamine administration.
Materials and Methods

Animals
Male Wistar rats (Harlan, Horst, The Netherlands) between 350 and 400 g body weight (BW), housed under constant conditions of temperature (21G1 8C) and humidity (60G2%) with a 12 h light:12 h darkness schedule (lights on at 0700 h), were used in all experiments. Food and drinking water were available ad libitum. All of the following experiments were conducted with the approval of the Animal Care Committee of the Royal Netherlands Academy of Arts and Sciences.
T 1 AM and T 0 AM T 1 AM-HCl (391 g/mol) and T 0 AM-HCl (264 g/mol) were synthesized as previously reported (Hart et al. 2006) and dissolved in 20% DMSO and 80% saline (vehicle) at a concentration of 40 mg/ml.
Experimental groups
Two independent studies were performed. For the first study, permanent jugular vein and carotid artery cannulae were placed in rats (nZ22) under anesthesia (see below). Animals were allowed to recover from the surgery for 8 days prior to any further manipulations. Each rat thus cannulated received an i.p. bolus infusion of 50 mg/kg of T 1 AM (nZ7), 50 mg/kg of T 0 AM (nZ8), or an equal volume (500 ml) of vehicle (nZ7). For the second study, rats (nZ31) were equipped with a guide cannula placed into the left lateral cerebral ventricle in addition to the carotid artery and jugular vein cannulae. Rats thus cannulated received an i.c.v. 100-fold lower dose (0 . 5 mg/kg) of either T 1 AM (nZ9), T 0 AM (nZ8), or DMSO-saline vehicle (nZ8) in a volume of 4 ml. To control for the possibility that any observed effect of the i.c.v.-infused thyronamines was somehow due to spillover into the circulation, an additional group of cannulated rats was infused intravenously with 0 . 5 mg/kg T 1 AM (nZ3) and T 0 AM (nZ3) in a volume of 500 ml. In both of these experiments, before and 120 min after i.p. or i.c.v. bolus infusion, isotope dilution and blood sampling were conducted to permit measurement of endogenous glucose production (EGP), and the concentration of plasma glucose, insulin, glucagon, corticosterone, thyroid stimulating hormone (TSH), T 3 and T 4 concentrations.
Surgery
Animals were anaesthetized using a mixture of Hypnorm ( Janssen; 0 . 05 ml/100 g BW, i.m.) and Dormicum (Roche; 0 . 04 ml/100 g BW, s.c). Vascular and i.c.v. cannulae were fixed with dental cement to four stainless-steel screws inserted into the skull. Post-operative care was provided by s.c. injection of 0 . 01 ml/100 g BW of Temgesic (Schering-Plough, Utrecht, The Netherlands). In all animals, an intra-atrial silicone cannula was implanted through the right jugular vein and a second silicone cannula was placed in the left carotid artery for isotope infusion and blood sampling as described previously (Klieverik et al. 2008) . For the second study, stainless-steel i.c.v. cannulae were implanted into the left cerebral ventricle using the following stereotaxic coordinates: anteroposterior: K0 . 8 mm; lateral: C2 . 0 mm; ventral: K3 . 2 mm, with the toothbar set at K3 . 4 mm. Guide cannula placement was confirmed by dye (4 ml of ethylene blue) injection and inspection post-mortem. Only animals that showed staining of the left lateral cerebral ventricle and third cerebral ventricle were included in the final analysis.
Stable isotope dilution and systemic versus central thyronamine administration
Eight days post-surgery, stable isotope dilution was performed in combination with the administration of synthetic thyronamines. Animals weighed between 335 and 380 g. BW increased in all groups during the 3 days preceding the experimental infusions, indicating recovery from surgery and a positive energy balance. One day before the experimental infusions, rats were connected to a metal collar to which polyethylene tubing (for blood sampling and infusion) was attached and kept out of reach of the animals by a counterbalanced beam. This permitted all subsequent manipulations to be performed outside the cages without handling the animals (Klieverik et al. 2008) . For determining basal plasma concentrations of TSH, T 3 , and T 4 , a blood sample was obtained at 1400 h. On the day of thyronamine administration, food was removed from the cages 4 h (w0830 h) before the first basal measurements. At w1100 h, a blood sample was taken (200 ml, tZK110 min) for determination of background isotopic enrichment. Subsequently, a primed (8 . 0 mmol in 5 min) continuous (16 . 6 mmol/h) infusion of the stable isotope tracer [6,6-2 H 2 ]-glucose (O99% enriched; Cambridge Isotope Laboratories, Cambridge, MA, USA) was started using an infusion pump (Harvard Apparatus, Holliston, MA, USA). After an equilibration period of 90 min, additional blood samples (200 ml) were obtained for the determination of basal plasma glucose, isotopic enrichment (tZK20, K10 and 0 min), plasma corticosterone (tZK20 and 0 min), insulin, and glucagon (tZ0 min) concentrations.
After the tZ0 blood sample, in study 1, animals received an i.p. bolus of either T 1 AM, T 0 AM (50 mg/kg in 500 ml), or vehicle. In study 2, again after the tZ0 blood sample, animals received an i.c.v. bolus infusion of either T 1 AM, T 0 AM (0 . 5 mg/kg in 4 ml), or vehicle delivered through the i.c.v. cannula in 105 s using a Hamilton syringe. After i.p. or i.c.v. bolus infusion, blood samples were obtained for measurement of glucose concentration, isotopic enrichment (5, 10, 20, 30, 45, 60, 75, 90 , and 120 min), plasma corticosterone (tZ10, 20, 30, 60, and 120 min), plasma insulin, glucagon (tZ10, 60 and 120 min), and plasma TSH, T 3 , and T 4 concentrations (tZ120 min).
Plasma hormone and isotope analyses
Plasma glucose concentration was determined in triplicate by a glucose oxidase method (Boehringer Mannheim). Plasma glucagon and corticosterone were measured using a commercially available RIA (LINCO Research, St Charles, MO, USA and ICN Biomedicals, Costa Mesa, CA, USA respectively). Plasma concentrations of T 3 and T 4 were determined by an in-house RIA (Kalsbeek et al. 2000) , with inter-and intra-assay variation coefficients (CV) of 7-8 and 3-4% (T 3 ), and 3-6 and 2-4% (T 4 ) respectively.
Detection limits for T 3 and T 4 were 0 . 3 and 5 nmol/l respectively. Plasma TSH concentrations were determined by a chemiluminescent immunoassay (Immulite 2000, Diagnostic Products Corp., Los Angeles, CA, USA) using a rat-specific standard. The inter-and intra-assay CV's for TSH were !4 and 2% at G3 . 5 mU/l respectively with a detection limit of 0 . 40 mU/l. Plasma insulin was measured by a commercially available ELISA (Mercodia, Uppsala, Sweden; Ackermans et al. 2008) . The inter-and intra-assay CV's were 4 and 2%, detection limit 13 pmol/l. All samples were measured in duplicate, i.e. two tubes were analyzed per plasma sample. Glucose enrichment was measured as previously described (Ackermans et al. 2001 ). The [6,6-2 H 2 ]-glucose enrichment (tracer/tracee ratio) interassay CV was 1%, the intra-assay CV 1%, and the detection limit 0 . 04%.
Calculations and statistical analysis
EGP was calculated from isotope enrichment and plasma glucose concentration using modified forms of steady-state (basal) and non-steady-state (after thyronamine infusion) Steele equations (Steele 1959) . Data were analyzed by twoway ANOVA with repeated measurements, with treatment group (T 1 AM, T 0 AM, or Veh) and time as dependent factors. Significance was defined at P!0 . 05 using paired t-tests (i.e. within treatment groups) and independent t-tests (i.e. between treatment groups) to identify experimental groups that differed significantly. The SPSS statistical software program version 16.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Data are presented as meanGS.E.M.
Results
In two independent studies, eight groups of rats were investigated. In the first study, rats received an i.p. bolus infusion of either T 1 AM (50 mg/kg, nZ7), T 0 AM (50 mg/kg, nZ8), or vehicle (nZ7). In the second study, rats were intracerebroventricularly infused with a 100-fold lower dose (i.e. 0 . 5 mg/kg) of either T 1 AM (nZ9), T 0 AM (nZ8), or vehicle (nZ8). To address the possibility that any physiologic response observed following i.c.v. infusion of the thyronamines was due to the peripheral action of drug that spilled over into the circulation, two additional groups of animals were intravenously infused with 0 . 5 mg/kg of T 1 AM (nZ3) or 0 . 5 mg/kg of T 0 AM (nZ3).
Study #1: systemic thyronamine infusion
Rats injected i.p. with 50 mg/kg T 1 AM or 50 mg/kg T 0 AM exhibited a behavioral phenotype as described previously (Scanlan et al. 2004) . Interestingly, the animals injected with T 1 AM displayed the more robust phenotype even though the dose (on a per mole basis) was approximately half that of T 0 AM.
Glucose homeostasis: plasma concentration and endogenous production Systemic infusion of either T 1 AM or T 0 AM by the i.p. route of administration induced a rapid and significant increase in plasma glucose concentration (Fig. 1a) . The onset and magnitude of this effect was similar for the two compounds until 45 min post-infusion when the effect of T 0 AM apparently plateaued, while the T 1 AM-induced hyperglycemia continued to develop eventually reaching a maximum 371G27% of basal values 120 min after infusion.
Within 10 Glucoregulatory hormones Given the profound effect of T 1 AM and T 0 AM on plasma glucose and EGP, we characterized the status of three glucoregulatory hormones: insulin; glucagon; and corticosterone (Fig. 2) . Surprisingly, even though T 1 AM and T 0 AM (50 mg/kg, i.p.) produced hyperglycemia and elevated EGP, plasma insulin concentrations were unchanged relative to plasma from vehicleinjected rats (Fig. 2a) . By contrast, plasma glucagon concentrations were significantly increased within 10 min of either T 1 AM or T 0 AM administration (Fig. 2b) . However, by 60 min post-injection, the time-effect profiles of the two compounds had begun to diverge with T 0 AM's effect reaching a plateau at 240% (PZ0 . 007 T 0 AM versus Veh, tZ60) of basal levels, while T 1 AM's effect continued to develop for the duration of the experiment (447G44% of basal values at 120 min, P!0 . 0001 T 1 AM versus Veh; Fig. 2b ). Of note, the time-course profiles of plasma glucagon ( Fig. 2b ) and plasma glucose (Fig. 1a) in response to i.p. T 1 AM and T 0 AM were essentially superimposable. Plasma corticosterone displayed a significant increase in response to both T 1 AM-and T 0 AM-injected i.p., compared with vehicle-injected rats (Fig. 2c) . T 1 AM infusion induced a maximal increase at tZ60 min (482G106 vs 179G71% of basal levels at tZ60 min, T 1 AM versus Veh; PZ0 . 022).
T 0 AM infusion increased plasma corticosterone to a similar extent (393G59 vs 172G102% of basal levels at tZ120 min, T 0 AM versus Veh; PZ0 . 022). At no time point was there a difference in the corticosterone response between T 1 AMand T 0 AM-infused groups.
Plasma T 3 , T 4 , and TSH concentrations before and 120 min after i.p. T 1 AM, T 0 AM, and vehicle infusion are depicted in Table 1 . Within 120 min, both T 4 and TSH levels were significantly decreased in response to i.p. T 1 AM or, to a larger extent, i.p. T 0 AM (50 mg/kg). Intriguingly, T 3 levels were also decreased 120 min after i.p. T 0 AM (50 mg/kg) when compared with vehicle-injected rats. T 0 AM (0 . 5 mg/kg, i.c.v.) significantly elevated plasma glucose as well, but to a lesser degree than T 1 AM (maximum 134G6% at tZ45, P!0 . 0001 versus Veh; Fig. 3a) .
T 1 AM (0 . 5 mg/kg, i.c.v.) induced a rapid and significant increase in EGP (Fig. 3b) by 10 min post-infusion reaching a maximum 178G16% of basal values at 30 min (P!0 . 0001 versus Veh), which gradually decreased with time to 113G5% when the experiment was terminated at tZ120 min.
Although T 0 AM (0 . 5 mg/kg, i.c.v.) significantly increased EGP above basal levels (P!0 . 0001; tZ0 vs tZ10), its maximum effect (20G9% increase at tZ20; PZ0 . 069 versus Veh) was approximately one-third of T 1 AM's maximal effect (Fig. 3b) . Importantly, when T 1 AM or T 0 AM were infused intravenously at the dose that was used in the i.c.v. infusion experiments (0 . 5 mg/kg, T 1 AM nZ3, T 0 AM nZ3) neither thyronamine had any effect on plasma glucose concentrations, EGP, plasma insulin, nor glucagon at any time point when compared with basal values (data not shown). From tZ60, glucose concentration is higher in T 1 AM when compared with T 0 AM-treated rats (P!0 . 05). ANOVA RM factor time P!0 . 0001, time!group P!0 . 0001, and group P!0 . 0001.
(b) Endogenous glucose production (EGP) before and after i.p. bolus infusion of T 1 AM, T 0 AM, or vehicle. From tZ10 and tZ20, EGP is higher in T 1 AM-and T 0 AM-infused rats respectively, when compared with vehicle (P!0 . 05). From tZ60, EGP is lower in T 0 AM relative to T 1 AM-treated animals (P!0 . 05). From tZ90, EGP in T 0 AM-treated rats is not different from vehicle rats.
ANOVA RM factor time P!0 . 0001, time!group P!0 . 0001, and group PZ0 . 001. L P KLIEVERIK, E FLIERS, A KALSBEEK and others . Central thyronamines and glucose metabolism When the absolute changes in plasma glucose concentration produced by 0 . 5 mg/kg T 1 AM i.c.v. and 50 mg/kg T 1 AM i.p. are compared over time, their profiles are practically superimposable for the first 30 min of exposure (Fig. 4a) . Thereafter, they diverged as the systemic effect of T 1 AM continued to develop. Plotting the absolute values for EGP in response to 0 . 5 mg/kg T 1 AM i.c.v. and 50 mg/kg T 1 AM i.p. revealed both routes of administration-produced identical profiles during the initial 20 min post-exposure (Fig. 4b) . However, at 30 min thereafter, the magnitude of the EGP effect elicited by T 1 AM i.c.v. was significantly greater than the effect of T 1 AM i.p. (Fig. 4b) .
Glucoregulatory hormones Similar to T 1 AM i.p. (Fig. 2a) , neither T 1 AM-nor T 0 AM-administered i.c.v. induced a significant change in plasma insulin content (Fig. 5a) . Although there was a trend for insulin to decrease 10 min after i.c.v. infusion of T 1 AM, this response failed to achieve statistical significance (PZ0 . 063; Fig. 5a ).
Plasma glucagon increased by 155% (from 69G10 to 176G20 pg/ml) 10 min after i.c.v. T 1 AM infusion (P!0 . 0001 versus Veh). During the same time period, T 0 AM i.c.v. also significantly increased plasma glucagon, but only by 58% (PZ0 . 004 versus Veh). Interestingly, the magnitude of T 1 AM's impact on circulating glucagon levels was dependent on the route of administration with i.c.v. infusion producing a greater effect in the first 10 min than i.p. administration (108G21 vs 50G11 pg/ml respectively; PZ0 . 044). Unlike the sustained elevation that followed i.p. administration of either T 1 AM or T 0 AM, plasma glucagon returned to basal levels within 60 min of infusing either compound i.c.v. (Fig. 5b) .
Plasma corticosterone concentrations were significantly increased following i.c.v. infusion of either 0 . 5 mg/kg T 1 AM or T 0 AM ( Fig. 5c ) with both treatments producing nearly equivalent maximum effects by tZ20 min post-injection (delta corticosterone tZ20 vs tZ0; 6G44 ng/ml Veh i.c.v., 206G58 ng/ml T 1 AM i.c.v., 296G49 ng/ml T 0 AM i.c.v., PZ0 . 02 T 1 AM versus Veh, P!0 . 0001 T 0 AM versus Veh).
Plasma T 3 , T 4 , and TSH concentrations before and after central (i.c.v.) infusion of either T 1 AM, T 0 AM, or vehicle (saline-DMSO) infusion are shown in Table 2 . Although plasma T 3 , T 4 , and TSH were found to decrease in all treatment groups by 120 min post-i.c.v. bolus infusion, neither i.c.v. T 1 AM nor T 0 AM had a statistically significant effect on plasma T 3 , T 4 , or TSH compared with vehicle i.c.v. (tZ0) and after i.p. injection of T 1 AM, T 0 AM, or vehicle. From tZ10, glucagon is higher in both T 1 AM-and T 0 AM-treated rats relative to vehicle rats (*P!0 . 05 versus Veh). At tZ60, glucagon concentration is higher in T 1 AM when compared with T 0 AM-treated rats (^PZ0 . 05 T 0 AM versus T 1 AM). ANOVA RM factor time P!0 . 0001, time!group P!0 . 0001, and group PZ0 . 001. (c) Plasma corticosterone concentration before (tZK20 and tZ0 min) and after (tZ5-120 min) i.p. injection of T 1 AM, T 0 AM, or vehicle. T 0 AMtreated animals have higher plasma corticosterone from tZ30 and T 1 AM-treated animals only on tZ60 when compared with vehicle
Discussion
In an effort to determine whether the thyronamines T 1 AM and T 0 AM can affect glucose homeostasis by acting directly on the brain, we compared their physiologic consequences following systemic and central administration. The major finding of our study is that central administration of low-dose (i.e. 1% of the systemic dose) T 1 AM acutely increases EGP and plasma glucose concentration to a similar -or even greater -extent compared with systemic T 1 AM, concomitant with an increase in plasma glucagon and corticosterone concentrations. Similar effects were observed following central T 0 AM infusion, albeit to a lesser extent. When administered intravenously, the same low dose of T 1 AM and T 0 AM, which was effective centrally, had no detectable effect on plasma glucose or EGP; thus excluding the possibility that the observed responses were the result of leakage of the centrally administered compound into the circulation and acting peripherally.
Rats infused intraperitoneally with T 1 AM, and to a lesser extent T 0 AM, exhibited a behavioural phenotype within minutes of administration, which was remarkably similar to the fully reversible behavioural changes reported earlier in mice (Scanlan et al. 2004 , Doyle et al. 2007 . In short, animals exhibited a decrease in overall locomotor activity and responsiveness to external stimuli (visual and auditory), while reflexes were preserved. Furthermore, the hyperglycemia that develops in mice (Regard et al. 2007) following thyronamine exposure also is seen in rats (Fig. 1a) . Moreover, we show for the first time that the hyperglycemia induced by the thyronamines T 1 AM and (to a lesser extent) T 0 AM occurs simultaneously with a rapid (i.e. within 10 min), w50% increase in EGP that was maintained for the duration of the experiment (Fig. 1b) .
With respect to the systemic administration of thyronamines, there are several mechanisms that may contribute to the alterations in glucose metabolism we observed. First, plasma glucagon increases rapidly in response to systemic T 1 AM and T 0 AM administration, concomitant with the increase in plasma glucose and EGP. It was expected that the thyronamine-induced hyperglycemia (up to 22 mmol/l; Fig. 1a) would provoke a considerable insulin response. However, plasma insulin did not change in spite of the overt hyperglycemia produced by either thyronamine. The plasma glucagon increase together with this inadequate insulin response is likely to be causal factors in the increase in plasma glucose and EGP induced by thyronamines. These effects on There is no significant difference between basal samples of any group. From tZ10, EGP in T 1 AM-infused rats is higher compared with vehicle rats (P!0 . 05). In T 0 AM rats, EGP at tZ30, 45, 90, 105, and 120 min is higher relative to vehicle-infused rats (P!0 . 05). From tZ20 to tZ90, EGP is higher in T 1 AM relative to T 0 AM-infused rats (P!0 . 05). ANOVA RM factor time P!0 . 0001, time!group P!0 . 0001, and group PZ0 . 006.
plasma glucagon and insulin might be explained by direct actions of T 1 AM and T 0 AM on the pancreatic a and b-cells, supposedly by binding to GPCRs such as TAAR1 or ARa2 (Liggett 2004 , Scanlan et al. 2004 ) Indeed, pharmacological stimulation of ARa2 has been shown to induce hyperglycemia and inhibit insulin release (Angel et al. 1990) . Second, given the rapid onset of thyronamine-induced changes, it is possible that T 1 AM and T 0 AM activation of GPCRs expressed in hepatocytes underlies the stimulation of EGP we observed, analogous to the stimulation of b-ARs by norepinephrine.
With regard to the possible mechanisms underlying the effects of centrally administered thyronamines on glucose metabolism, it is interesting that concomitant with the rapid increase in EGP (Fig. 3b) , plasma insulin levels tended to decrease acutely after central administration of 0 . 5 mg/kg T 1 AM (Fig. 5a ) in contrast to systemically (i.e. i.p.) administered drug. In addition, after i.c.v. infusion of 0 . 5 mg/kg T 1 AM, there was a rapid increase in plasma glucagon (Fig. 5b) , which was more pronounced than the early glucagon increase after systemic thyronamine infusion. No change in EGP, plasma insulin, and glucagon levels was observed after i.v. infusion of 0 . 5 mg/kg T 1 AM, confirming that T 1 AM-imposed actions on the CNS are causal to these phenomena. This dependence of thyronamine effects on the route of administration point to neural or (neuro)transmitter type, rather than humoral type of actions. Indeed, it has been demonstrated that T 1 AM modulates synaptosomal transport of neurotransmitters such as dopamine and norepinephrine (Snead et al. 2007 ), supposedly by behaving as endogenous monoamine reuptake inhibitors (Weatherman 2007) . In addition, low-dose T 1 AM administration in the lateral cerebral ventricles and in the arcuate nucleus was recently reported to rapidly increase food intake (Dhillo et al. 2008) . The effects of thyronamines on plasma insulin and glucagon in the present study may be explained by increased sympathetic tone in the pancreas, mediated via central thyronamine actions. In addition, centrally administered thyronamines might stimulate autonomic outflow from the hypothalamus to the liver thereby elevating EGP. In support of this conjecture is accumulating evidence demonstrating the brain's important role, particularly the hypothalamus, in regulating hepatic glucose metabolism via sympathetic and parasympathetic projections to the liver (Obici et al. 2002 , Kalsbeek et al. 2004 , Pocai et al. 2005 , Klieverik et al. 2008 .
As thyronamines have been hypothesized to constitute a novel aspect of TH biology (Liggett 2004 , Scanlan et al. 2004 , it was of interest to assess how thyroid-related parameters in euthyroid animals responded to synthetic thyronamines. Systemic infusion of these compounds, in particular T 0 AM, depressed plasma TSH, T 4 , and T 3 levels, whereas central administration had no such effect. These responses could represent a state reminiscent of the non-thyroidal illness syndrome (Fliers et al. 1997 , Boelen et al. 2004 , Adler & Wartofsky 2007 . Although it is conceivable that the thyronamines altered TH secretion by decreasing TSH release from the pituitary, the observation that central thyronamine administration does not induce plasma TH alterations relative to vehicle, argues against this possibility. Finally, an effect of thyronamines on plasma concentrations of iodothyronines via interaction with the deiodinase enzymes seems less likely as T 1 AM does not interfere with D1-mediated iodothyronine deiodination in vitro (Piehl et al. 2008) .
Systemic thyronamine administration produced significant increases in plasma corticosterone levels that were similar in T 1 AM-and T 0 AM-infused rats (Fig. 2c) , and could be recapitulated by low-dose (0 . 5 mg/kg) i.c.v. infusion of (Fig. 5c) , suggesting that these represent central effects of thyronamines on the hypothalamus-pituitary-adrenal axis. The elevated corticosterone could contribute in a limited way to the hyperglycemic state but, more importantly, because in both experiments the hyperglycemia was much more pronounced in T 1 AM when compared with T 0 AM-infused animals, it is unlikely to account for the major glucose increase induced by systemic and central T 1 AM.
There are several mechanisms by which circulating thyronamines might exert their actions in the CNS. First, there could be passive or active transport of circulating thyronamines across the blood-brain barrier, the latter analogous to iodothyronines (Dratman et al. 1991) . Second, circulating thyronamines might bind cell-surface receptors in the plasma membrane of neurons located in circumventricular nuclei such as the arcuate nucleus where the blood-brain barrier is absent. The arcuate nucleus is known to mediate central actions of the peptide hormones like insulin and leptin via locally expressed leptin and insulin receptors (Niswender & Schwartz 2003) , and TAAR1 is expressed in the arcuate nucleus (Borowsky et al. 2001) . However, our finding that the EGP increase is not as robust following central administration of thyronamines as it is after systemic administration suggests their central actions alone are insufficient to account for the persistent EGP increase and hyperglycemia. Consistent with this interpretation are the results from a recent study in which mice pre-treatment with 6-hydroxydopamine still developed hyperglycemia and hypoinsulinemia following i.p. administration of T 1 AM, suggesting that these T 1 AM-induced alterations can occur in the absence of sympathetic signalling (Regard et al. 2007 ). Another possibility is that thyronamines impose both peripheral and central actions on glucose metabolism, occurring independently. In this intriguing scenario, central actions could be mediated by thyronamines formed locally in the brain, by conversion from iodothyronines such as T 4 , T 3 , and/or reverse T 3 .
The rapid and pronounced metabolic effects produced by central administration of T 1 AM and T 0 AM suggest that one or more receptors mediate their actions. Indeed, T 1 AM and T 0 AM dose dependently activate the Gs protein-coupled TAAR1 receptor (Borowsky et al. 2001 , Bunzow et al. 2001 , Grandy 2007 , Wainscott et al. 2007 . TAAR1 belongs to a large family of related receptors (Borowsky et al. 2001 , Grandy 2007 , and this receptor's mRNA is expressed in a wide variety of tissues including many areas of the brain (c) Plasma corticosterone concentration before (tZK20 and 0 min) and after (tZ5 to tZ120 min) i.c.v. bolus infusion of T 1 AM, T 0 AM, or vehicle. Circulating corticosterone levels rapidly increase following the infusion of T 1 AM or T 0 AM at tZ20 and tZ10 min when compared with vehicle respectively. Note that T 1 AM-and T 0 AM i.c.v.-infused groups do not differ at any time point, except for tZ5 min. *P!0 . 05 versus vehicle i.c.v.,^P!0 . 01 T 1 AM versus T 0 AM i.c.v. ANOVA RM factor time P!0 . 0001, time!group PZ0 . 002, and group PZ0 . 001. L P KLIEVERIK, E FLIERS, A KALSBEEK and others . Central thyronamines and glucose metabolism (Borowsky et al. 2001 , Bunzow et al. 2001 . The fact that the rank order of potency as a TAAR1 agonist in vitro, T 1 AM being more potent than T 0 AM (Scanlan et al. 2004) , is also reflected in the metabolic responses described in the present study, fits with the notion that TAAR1 may mediate some actions of T 1 AM and T 0 AM. In addition, Regard et al. (2007) have recently shown that whereas T 1 AM induces hyperglycemia after systemic administration in wild-type mice, this effect is lost in ARa2-deficient mice as well as mice pretreated with the ARa2 antagonist yohimbine. Moreover, by using a transgenic approach, they provided strong evidence that the hyperglycemia and concurrent hypoinsulinemia following T 1 AM infusion in mice was dependent upon pancreatic Gi protein-coupled receptor expression. Collectively, these data suggest that, at least for the effects of systemically administered T 1 AM on glucose metabolism, ARa2 is important. Interestingly, ARa2 are highly expressed in the hypothalamus as well and contribute to the hypothalamic regulation of sympathetic outflow (Li et al. 2005) , supporting their possible involvement in mediating effects of centrally administered thyronamines.
To date, every published metabolic and physiologic study involving thyronamines, including this one, has relied on the administration of synthetic material (Braulke et al. 2007 , Chiellini et al. 2007 , Doyle et al. 2007 , Regard et al. 2007 . Therefore, the biological significance of endogenous thyronamines remains to be addressed. In this context, it will be important to establish how and where these compounds are synthesized. Although there is currently no direct evidence in the literature for in vivo conversion of thyronamines from precursor iodothyronines (i.e. T 3 , T 4 , and rT 3 ), the enzymes indispensable for such conversion such as aromatic amino acid decarboxylase for decarboxylation and iodothyronine deiodinases type 2 and 3 for deiodination are widely distributed in the CNS, and indeed within the hypothalamus (Zhu & Juorio 1995 , Tu et al. 1997 , Alkemade et al. 2005 , Lechan & Fekete 2005 ). An important remaining question is whether the metabolic effects in the present and other studies represent physiological or pharmacological effects of thyronamines. The systemic dose of T 1 AM used in our study has been shown to induce a tenfold increase in plasma T 1 AM concentration within 3 h after infusion in Siberian hamsters (Braulke et al. 2007 ). However, there are currently no data on the pharmacokinetic characteristics (distribution volume, clearance, and binding to plasma proteins) of thyronamines, and at present it is unknown how thyronamine tissue concentrations during experimental manipulations compare to their concentrations under more physiologic conditions.
We conclude that central administration of a low dose of either T 1 AM or T 0 AM can acutely induce increased EGP and hyperglycemia, concomitant with increased plasma glucagon, corticosterone, and a deficient insulin response. These changes are very similar to the acute changes observed after systemic T 1 AM and T 0 AM administration. Our data indicate that thyronamines can act centrally in order to modulate glucose metabolism. 
